Fig. 4

Upregulated TRAF2 is associated with a poor clinical prognosis in ccRCC. (A) Heatmap of expression patterns in TCGA-KIRC for the five genes that make up the model. (B) TRAF2 mRNA expression in 539 ccRCC tissues as compared to 72 adjacent noncancerous tissues from TCGA-KIRC data. (C, D) RT-qPCR and Western Blot analysis of TRAF2 expression in 16 paired ccRCC and adjacent noncancerous tissues. (E) Immunohistochemical (IHC) analysis of TRAF2 in a ccRCC tissue microarray (TMA) 96 ccRCC tumor and adjacent noncancerous pairs (left panel) and quantification of TRAF2 expression by IHC analysis in ccRCC TMA samples as compared to normal (right panel). (F) Protein and mRNA expression levels of TRAF2 in HK2 and ccRCC cell lines. (G) Kaplan-Meier OS analysis of TRAF2 expression in patients with ccRCC (n = 96, p = 0.002, log-rank test). (H) Multivariable analyses were performed in the ccRCC cohort. All bars correspond to 95% CIs. Error bars, SEM; **, p < 0.01; ***, p < 0.001, ****, p < 0.0001